Senderra Specialty Pharmacy

Overview

Senderra Specialty Pharmacy is an independent national specialty pharmacy for complex and chronic therapies, combining specialty dispensing with access operations: benefit verification, prior authorization support, ePA-enabled prescriber workflows, copay and affordability routing, patient onboarding, clinical therapy management, SMS patient updates, and manufacturer reporting. Nautic Partners closed a majority investment in Q1 2026; existing management retained a minority stake and continues to lead daily operations.

Senderra is NOT a PBM-owned specialty pharmacy, an oncology specialist, a stand-alone hub, or a high-volume retail dispenser. It is most relevant when a manufacturer needs a non-PBM-owned national specialty pharmacy with strong prescriber-office workflow support, modern digital tools, and manufacturer-facing visibility — CarePath for case management, SenderraCare+ for patient onboarding and engagement, and Pharma Navigator for field reimbursement visibility into referral and treatment status.

Specialty Pharmacy Capability Model

The framework below standardizes how Rx Almanac evaluates specialty-pharmacies capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Senderra Specialty Pharmacy is evaluated as independent national specialty pharmacy for complex and chronic therapies, combining specialty dispensing with access operations: benefit verification, prior authorization support, ePA-enabled prescriber workflows, copay and affordability routing, patient onboarding, clinical therapy management, SMS patient updates, and manufacturer reporting.

Capability	Buyer should compare	Senderra Specialty Pharmacy readout
Specialty dispensing and channel access	Licensed dispensing footprint, payer network access, LDD participation, referral capture, and ability to serve the target patient geography.	Major fulfillment handoff. Senderra positions as an independent national specialty pharmacy with broad chronic and complex therapy coverage.
Benefits, PA, and reimbursement support	Benefit investigation, PA support, appeals coordination, copay/PAP routing, and reimbursement troubleshooting at the pharmacy edge.	Major coverage workflow. Senderra’s model and current product materials center on patient / physician intake, ePA-enabled prescriber support, prior authorization workflows, and access support. Documented capability. Senderra markets manufacturer and patient-support services that include financial-assistance coordination.
Clinical therapy management and adherence	Pharmacist counseling, disease-specific protocols, refill outreach, injection training, persistence programs, and clinical escalation.	Documented capability. SenderraCare+ and CarePath are positioned around therapy onboarding, adherence, and ongoing patient management.
Cold chain, REMS, and complex handling	Temperature control, REMS certification, hazardous/controlled-substance handling, biologics, CGT, and other special distribution requirements.	Active investment area. The Hyperscience collaboration targets patient and physician onboarding, communications, and document-intensive workflows.
Manufacturer data and outcomes reporting	Status feeds, dispense data, adherence/outcomes reporting, inventory visibility, and reporting cadence suitable for launch governance.	Differentiator. Pharma Navigator and CarePoints are manufacturer-facing and designed to give field reimbursement, hub, and partner teams clearer patient-status, refill, and reporting visibility.
Site-of-care, infusion, or health-system coordination	Home infusion, ambulatory infusion, provider-office coordination, health-system capture, and buy-and-bill support where relevant.	Not the main buying reason for Senderra Specialty Pharmacy; validate only if the SOW includes site-of-care, infusion, or health-system coordination.

Buyer Fit

• Buyer trigger: Include Senderra when prescriber-office workflow, prior authorization execution, affordability support, patient onboarding, and launch visibility matter as much as dispensing scale.
• Profile signal: One of the largest independent national specialty pharmacies; Pharma Navigator gives manufacturer field reimbursement teams near-real-time visibility, and Hyperscience automation handles 86,500+ inbound communications per month.
• Best-fit therapies: Dermatology, immunology / autoimmune, gastroenterology, neurology, endocrine, hematology, respiratory, ophthalmology, and selected oncology therapies with high access friction.
• Less ideal fit: Buy-and-bill infusion programs, oncology launches that need oncology-specialist scale, hospital-owned specialty pharmacy capture strategies, or programs that rely on PBM-mandated specialty routing rather than independent dispensing.
• Commercial fit: Pricing is undisclosed; assume RFP-led scope with data rights, status taxonomy mapping, service-level commitments, and hub handoffs defined in the SOW.
• Commercial diligence: Target-product payer access, limited-distribution eligibility, manufacturer data rights, service-level commitments, hub handoffs, and whether Senderra’s digital workflow can be configured to the brand’s status taxonomy.

Differentiators

• Independent national positioning: Senderra gives manufacturers an alternative to PBM-owned specialty pharmacies when channel neutrality and manufacturer data comfort matter.
• CarePath / CarePoints workflow backbone: Public materials describe proprietary tools for patient case management, therapy management, and partner reporting.
• Prescriber and patient workflow tools: Current product materials add physician portal, ePA, SMS patient updates, and copay-program support to the access workflow.
• SenderraCare+ patient journey: The patient-facing platform supports digital onboarding and therapy-management workflows for specialty medications.
• Pharma Navigator: The manufacturer-facing platform is built to give field reimbursement specialists and hub liaisons cleaner visibility into referrals, treatment status, and refills.
• Automation investment: The Hyperscience collaboration targets high-volume intake and communication workflows so clinical teams can spend more time on exceptions and patient support.

RFP Questions

• Which payers and limited-distribution networks can Senderra access for the target product at launch and post-launch?
• What exact status events will the manufacturer receive, how often, and through which feed or dashboard?
• How will Senderra coordinate with the manufacturer hub, field reimbursement team, copay program, and patient services vendor?
• Which prior authorization, appeal, affordability, and abandonment workflows are handled internally versus through partners?
• Which physician-portal, ePA, SMS patient-update, CarePath, CarePoints, and copay-program features are included for the target brand?
• What therapy-specific clinical touchpoints, adherence protocols, and escalation paths will be configured for this product?
• How does Pharma Navigator map the brand’s preferred status taxonomy to Senderra’s internal workflow states?

Recent Activity

• 2026: Current Senderra pharma and product materials emphasized CarePath, CarePoints, physician portal / ePA, SMS patient updates, copay support, Pharma Navigator, and expanded oncology / ophthalmology specialty-page breadth.
• December 2025: SenderraRx announced a strategic growth investment from Nautic Partners, with the existing management team continuing to lead the business.
• September 2025: Senderra and Hyperscience announced a collaboration to automate patient and physician onboarding and communication workflows using the Hyperscience Hypercell platform.
• September 2025: Senderra launched Pharma Navigator, a data-driven digital solution for pharmaceutical manufacturers and field support teams.
• August 2025: Senderra added Lilly’s EBGLYSS to SenderraCare+ for moderate-to-severe atopic dermatitis patient support.
• August 2025: Senderra earned a second consecutive Inc. 5000 placement.
• July 2024: Senderra introduced SenderraCare+ as a digital patient journey solution for specialty therapy medications.